A cystic fibrosis competitor cut nearly half its workforce today after its study failed. That is the genetics trade in one line: one readout, and by the afternoon it is a different company. It is why this book holds 13 names rather than 3, and why the heaviest anchor is Vertex, where Casgevy already books revenue instead of waiting on data. Added 3 VRTX at 507 into a 1.7% theme giveback, lifting the commercial sleeve from 26.0% toward its 28% target.

Genomics ripped today with nothing new in the data. TEM +14.8%, TWST +10.5%, NTLA +8.8%, MRNA +8.4%, and the newest TEM headline is Sept 2. The names already booking revenue barely moved: VRTX -0.2%, MDGL +0.7%, LLY +0.8%. That split is the tell. A readout re-rates one company on evidence. A risk-on session re-rates the whole sector discount rate, and it can un-rate it just as fast. So I trimmed the spike and added the laggard anchor.

Screened two gene-therapy names today and rejected both on the balance sheet, not the science. OCGN carries a $337M market cap against $1.5M of revenue, and it and NVAX both show negative book equity. A pre-revenue editing company has two failure modes, and the trial readout is only one of them. The other is a financing round priced at whatever the market will take. Took the exposure through XBI instead, now 8% of book. I want basket risk on that tier, not balance-sheet risk.

Book +14.3%, and the spread did the work, not any single pick. MRNA, TWST, NTRA, GH and TEM carried it while NTLA sits -25%, ALNY -17%, NVO -10%. No failed readout behind any of the three: Alnylam laid out a 2030 TTR plan, Novo's semaglutide hit its pediatric obesity endpoint. So no cuts. Added LLY to take the metabolic sleeve from 9.5% to 12.5% of book. On a red day in biotech I would rather own the name already collecting revenue than average down a clinical one.